Three-year antibody persistence and safety after a single dose of combined haemophilus influenzae type b (Hib)-neisseria meningitidis serogroup c-tetanus toxoid conjugate vaccine in Hib-primed toddlers

Pediatric Infectious Disease Journal

Volumn 32, Issue 2, 2013, Pages 169-174

  Booy, Robert ^a   Richmond, Peter ^b   Nolan, Terry ^c   McVernon, Jodie ^c   Marshall, Helen ^d   Nissen, Michael ^e   Reynolds, Graham ^k   Ziegler, John B ^f   Stoney, Tanya ^g   Heron, Leon ^a   Lambert, Stephen ^e   Mesaros, Narcisa ^h   Peddiraju, Kavitha ⁱ   Miller, Jacqueline M ^j  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY OF ADELAIDE   (Australia)

^e ROYAL CHILDREN'S HOSPITAL   (Australia)

^f SYDNEY CHILDREN'S HOSPITAL   (Australia)

^g UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^h GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

ⁱ GlaxoSmithKline Pharmaceuticals Ltd   (India)

^j GLAXOSMITHKLINE   (United States)

^k NONE

more..

Author keywords

antibody persistence; Haemophilus influenzae type b; Neisseria meningitidis serogroup C; toddlers

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B VACCINE; TETANUS TOXOID;

ANTIBODY TITER; ARTICLE; CHILD; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; INFANCY; INFANT; MALE; MULTICENTER STUDY; NEISSERIA MENINGITIDIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; VACCINATION;

ANTIBODIES, BACTERIAL; CHILD, PRESCHOOL; FEMALE; HAEMOPHILUS VACCINES; HUMANS; IMMUNIZATION; MALE; TETANUS TOXOID; VACCINES, CONJUGATE;

EID: 84873056841     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3182787bff     Document Type: Article

References (14)

1. Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using effcacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol. 2003;10:780-786.
2. Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection-serum bactericidal antibody activity. Vaccine. 2005;23:2222-2227.
3. Auckland C, Gray S, Borrow R, et al. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J Infect Dis. 2006;194:1745-1752.
4. Booy R, Richmond P, Nolan T, et al. Immediate and longer term immunogenic-ity of a single dose of the combined haemophilus infuenzae type B-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in primed toddlers 12 to 18 months of age. Pediatr Infect Dis J. 2011;30:340-342.
5. Käyhty H, Peltola H, Karanko V, et al. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus infuenzae type b. J Infect Dis. 1983;147:1100.
6. Anderson P. The protective level of serum antibodies to the capsular poly-saccharide of Haemophilus infuenzae type b. J Infect Dis. 1984;149:1034-1035.
7. Borrow R, Andrews N, Findlow H, et al. Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and haemophilus infuenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine. Clin Vaccine Immunol. 2010;17:154-159.
8. Díez-Domingo J, Cantarino M V, Torrentí JM, et al.; MenC Study Group. A randomized, multicenter, open-label clinical trial to assess the immuno-genicity of a meningococcal C vaccine booster dose administered to children aged 14 to 18 months. Pediatr Infect Dis J. 2010;29:148-152.
9. Khatami A, Snape MD, Davis E, et al. Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations. Vaccine. 2012;30:2831-2838.
10. Marshall GS, Mesaros N, Aris E, et al. Persistence of immunity three years after an investigational Haemophilus infuenzae type b and Neisseria men-ingitidis serogroups C and Y tetanus toxoid (HibMenCY-TT) conjugate vaccine. Paper presented at: 45th National Immunization Conference; March 28-31, 2011; Washington, DC. Abstract 25219.
11. Tejedor JC, Merino JM, Moro M, et al. Five-year Antibody Persistence and Safety Following a Booster Dose of Combined Haemophilus infuenzae Type b-Neisseria meningitidis Serogroup C-Tetanus Toxoid Conjugate Vaccine. Pediatr Infect Dis J. 2012;31:1074-1077.
12. Khatami A, Snape MD, John T, et al. Persistence of immunity following a booster dose of Haemophilus infuenzae type B-Meningococcal serogroup C glycoconjugate vaccine: follow-up of a randomized controlled trial. Pedi-atr Infect Dis J. 2011;30:197-202.
13. Trotter CL, Borrow R, Findlow J, et al. Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era. Clin Vaccine Immunol. 2008;15:1694-1698.
14. De Voer RM, Mollema L, Schepp RM, et al. Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal c conjugate vaccine. PLoS ONE. 2010;5:e12144.